Kaynaklar
- Acar A, Yeğenoğlu S. Akılcı ilaç kullanımı penceresinden farmakoekonomi ve hastane formülerleri. Ankara Ecz. Fak. Derg. 2005; 34: 207–218.
- Acar A, Yeğenoğlu S. Sağlık ekonomisi perspektifinden farmakoekonomi. Hacettepe Üniversitesi Ecz. Fak. Derg. 2006; 26: 39–55.
- Peter J, Neumann ScD. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics:Implication for schizophrenia treatment. J Clin Psychiatry 1999; 60: 9–16.
- Maj M, Sartorius N (editor). In Schizophrenia John Wiley & Sons Ltd, 1999; pp: 407–481.
- Özdemir O. Temel farmakoekonomi ilkeleri. İyi Klinik Uygulamalar 2005; 11: 10–20.
- Çetin M, Açıkel C. Meta-analizler ışığında: Bütün antidepresanlar aynı mıdırı. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, 2009; 19: 87–92.
- Sullivan PW, Valuck R, Brixner DI, Armstrong EP. Managed care's response to a pharmacoeconomic model of serotonin reuptake inhibitors. P&T 2005; 30: 178–182.
- McFarland BH. Depression in managed care: costs of selective serotonin reuptake inhibitors. J Managed Care Pharm 2001; 7: 142–148.
- Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world: Effectiveness versus efficacy studies. Pharmacoeconomics 1999; 15: 423–434.
- Stewart A. Choosing an antidepressant: effectiveness based pharmacoeconomics. J Affect Disord 1998; 48: 125–133.
- Barrett B, Byford S, Knapp M. Evidence of cost-effective treatment for depression: a systematic review. J Affect Disord 2005; 84: 1–13.
- Einarson TR, Arikian S, Sweeney S, Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther. 1995; 17: 136–153.
- Andlin-Sobocki P, Rössler W. Cost of psychotic disorders in Europe. Eur J Neurol 2005, 12 (Suppl.1): S74–S77.
- Bhana N, Foster RH, Olney R, Plosker G.L. Olanzapine: An Updated Review of its Use in the Management of Schizophrenia. Drugs: 2001; 61: 111–161.
- Manning WG. Panel on cost—effectiveness in health and medicine recommendations: Identifying costs. J Clin Psychiatry 1999; 60(3): 54–55.
- Yıldız M, Cerit C. Şizofreni tedavisinin yıllık maliyeti: Bir üniversite hastanesi verilerinden yapılan hesaplama. Klinik Psikofarmakoloji Bülteni -Bulletin of Clinical Psychopharmacology 2006; 16: 239–244.
- Meltzer HY. Outcome in schizophrenia: Beyond symptom reduction. J Clin Psychiatry 1999; 60: 3–9.
- Bland RC. Psychiatric disorders in America: The epidemiologic catchment area study J Psychiatry Neurosci. 1992; 17: 34–36.
- Henry N, Smeltzer DJ. Şizofreni güncel tanı ve tedavi kitabı Çeviri editörü Köksal Alptekin. 1. baskı. AND Yayıncılık, 2005; 27–99.
- Rice DP, Miller IS. The economic burden of schizophrenia. In: Moscarelli M, Rupp A, Sartorıus N ed. handbook of mental health economics and health policies. John Wiley & Sons, 1996; 321–334.
- Kissling W, Höffler J, Seemann U, Müller P, Rüther E, Trenckmann U, Uber A, Graf von der Schulenburg JM, Glaser P, Glaser T, Mast O, Schmidt D. Direct and indirect costs of schizophrenia. Fortschr Neurol Psychiatr 1999; 67: 29–36.
- Tufan AE. Dikkat eksikliği-hiperaktivite bozukluğunda tedavi maliyetini öngörmek üzere bir kılavuz önerisi. Klinik Psikofarmakoloji Bülteni—Bulletin of Clinical Psychopharmacology 2009; 19: 208–210.